ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis

ErinDeRuggiero
Non-Personal Promotion

AaronDavis
Value & Access

BudBilanich
Success Coach

IraHaimowitz
Closed-Loop Marketing

EdCohen, PharmD, FAPhA
Pharmacy’s Significance

BrendaSnow
Authentic Patient Voice

JuliaLaurin
Medication Adherence

SarahCaldwell
Data & Analytics

DavidLinetsky
Point-of-Care Marketing

Lillie D.Shockney, RN, BS, MAS, HON- ONN-CG
The Treatment Experience

AdrienneStevens, EdD, MBA
HCP Insights

DonFeiler
Brand Engagement